Navigation Links
Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Date:3/12/2009

and commercialization of blinatumomab. MedImmune will complete the development of the commercial scale manufacturing process for blinatumomab at its cost. Upon the first marketing approval of blinatumomab in the United States, MedImmune will have a one-time option to reacquire the commercialization rights in North America at pre-defined terms.

Micromet's clinical development activities with blinatumomab in Europe will continue unchanged. With the return of control over the development of blinatumomab in North America, Micromet will be in a position to align the European and US development activities. Micromet will provide an update later this year on its plans for the development of blinatumomab in the United States.

The companies plan to initiate a research program for the development of a new BiTE antibody for the treatment of hematological cancers. MedImmune has an exclusive license to develop and commercialize the new BiTE antibody in North America, while Micromet owns all rights to the new BiTE antibody outside of North America. MedImmune will reimburse Micromet for its expenses in the performance of certain research and preclinical development activities to be conducted by Micromet. In addition, MedImmune will be required to make milestone payments upon the achievement of certain development milestones, and, if it receives marketing approval, to pay a royalty on net sales of the new BiTE antibody in North America.

Summary of Key Clinical Data Presented in 2008:

  • In December, Micromet presented clinical data on blinatumomab at the American Society of Hematology meetings in San Francisco. The presentations included an oral presentation of the phase 1 clinical trial data of blinatumomab in patients with relapsed non-Hodgkin's lymphoma and a poster presentation of the first interim data from its phase 2 clinical trial of blinatumomab in adult patients with acute lym
    '/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Micromet, Inc. Reports Third Quarter 2008 Financial Results
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
3. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
4. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
5. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
7. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... May 15, 2012, JoVE ( Journal of Visualized ... United States government,s Defense Threat Reduction Agency (DTRA). ... University,s Dr. Chris Schafmeister and State University of New York ... The support of scientists conducting research for DTRA has significant ...
... Reportlinker.com announces that a new ... its catalogue: , Neuroendocrine Carcinoma ... Forecast to 2019 ... Therapeutics - Pipeline Assessment and Market ...
... BGI, one of the world,s largest genomics organizations, ... been successfully installed at its facility in Shenzhen, China. The ... sequencing technologies and enhance BGI,s long read sequencing capability. ... a Roche Company, features the unique combination of long reads, ...
Cached Biology Technology:JoVE partners with US government to publish cutting-edge defense research 2Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 2Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 3Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 4Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 5Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 6Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 7Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 8Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 9Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 10BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research 2BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research 3
(Date:4/24/2014)... turtle is the largest river turtle in North America, ... almost a century. Now researchers from Florida and the ... one species but three. , Examining museum specimens ... in this ancient reptile. , Once heavily hunted for ... of Campbell,s Turtle Soup in the 1960s the ...
(Date:4/23/2014)... prevalence of asthma, allergies and other chronic inflammatory disorders ... in part to their reduced exposure to the microbes ... scientific paper. , The article, published in the journal ... living in urban centers who have less access to ... inflammation, a condition caused by immune system dysfunction. , ...
(Date:4/23/2014)... most in their mid-thirties and forties, face a ... within two decades. "Mutant" protein clusters, long blamed ... been the primary focus of therapies in development ... from Prof. Gerardo Lederkremer and Dr. Julia Leitman ... and Immunology, in collaboration with Prof. Ulrich Hartl ...
Breaking Biology News(10 mins):Two new US turtle species described 2Two new US turtle species described 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3On the defensive 2On the defensive 3
... A new study from researchers at Queen Mary, University of ... in self-managing their disease. People with diabetes have to ... their condition. This includes not only monitoring the level of ... restrictive diet but also social challenges such as negotiating relatives, ...
... N.Y. -- It turns out that the milk of human ... Research by psychologists at the University at Buffalo and ... part of the reason some people are kind and generous ... Poulin, PhD, assistant professor of psychology at UB, is the ...
... of the woodpecker,s resistance to head impact injury are ... group from the Key Laboratory for Biomechanics and Mechanobiology ... and Medical Engineering, Beihang University, and the School of ... out to study this problem. After 3 years of ...
Cached Biology News:Approach to diabetes self-management too narrow, study suggests 2Approach to diabetes self-management too narrow, study suggests 3Study finds peoples' niceness may reside in their genes 2Mechanical properties and microstructure of cranial and beak bones of the woodpecker and the lark 2
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
...
...
...
Biology Products: